1/13/2020 7:14:21 AM
Karyopharm Expects XPOVIO Unaudited Net Product Sales Of $17 Mln-$18 Mln For Q4 And $30 Mln-$31 Mln For 2019
10/1/2019 7:16:30 AM
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
10/1/2019 7:15:29 AM
Karyopharm Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/16/2019 7:17:40 AM
Karyopharm Enters Into Royalty Agreement With Healthcare Royalty Partners For Up To $150 Mln
7/5/2019 7:51:23 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) FY19 Rev. Estimate To 9.2 M From 5.5 M
7/5/2019 7:51:09 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q4 19 Rev. Estimate To 5.8 M From 4.2 M
7/5/2019 7:50:58 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q3 19 Rev. Estimate To 3.3 M From 1.2 M
7/5/2019 7:50:34 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) FY19 Estimate To -3.74 From -4.18
7/5/2019 7:50:18 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q4 19 Estimate To -0.79 From -1.04
7/5/2019 7:50:05 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) Q3 19 Estimate To -0.85 From -0.99
7/5/2019 7:49:46 AM
Wedbush Is Increasing Karyopharm Therapeutics Inc. (KPTI) Q2 19 Estimate To -1.01 From -1.07
7/3/2019 1:39:03 PM
Karyopharm Announces FDA Approval Of XPOVIO For Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
3/15/2019 6:19:28 AM
Wedbush Reiterates Karyopharm Therapeutics Inc. (KPTI) At Outperform With $6 Price Target
2/27/2019 8:10:16 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) FY19 Estimate To -3.26 From -3.77
2/27/2019 8:09:58 AM
Wedbush Is Raising Karyopharm Therapeutics Inc. (KPTI) Q4 19 Estimate To -0.86 From -1.00